Antengene-B (06996) Issues Profit Alert, Expects First Half Profit of Approximately RMB 195 Million to RMB 238 Million

Stock News

Jul 28

Antengene-B (06996) has released an announcement. The group anticipates achieving revenue between RMB 490 million and RMB 536 million for the six months ending June 30, 2026, compared to revenue of approximately RMB 53.2 million for the six months ending June 30, 2025.

For the current period, a profit ranging from RMB 195 million to RMB 238 million is expected, in contrast to a loss of approximately RMB 76.4 million in the corresponding period last year.

The projected increase in revenue and the turnaround from loss to profit are primarily attributed to: an out-licensing and collaboration agreement with UCB for ATG-201 (CD19×CD3), which took effect from March 2026 and served as the main revenue driver for the period. As previously disclosed in the group's announcement dated July 13, 2026, the group received a $60 million upfront payment from UCB; and an exclusive out-licensing and collaboration agreement with K2 Therapeutics for ATG-106 (CDH6×CD3), effective from June 2026, which generated additional revenue during the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1118235961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118235961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118235961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 06:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118235961","market":"hk","top_or_hot":-1,"title":"Antengene-B (06996) Issues Profit Alert, Expects First Half Profit of Approximately RMB 195 Million to RMB 238 Million","media":"Stock News","content":"<p><b>Antengene-B</b> (<b>06996</b>) has released an announcement. The group anticipates achieving revenue between RMB 490 million and RMB 536 million for the six months ending June 30, 2026, compared to revenue of approximately RMB 53.2 million for the six months ending June 30, 2025.<br><br>For the current period, a profit ranging from RMB 195 million to RMB 238 million is expected, in contrast to a loss of approximately RMB 76.4 million in the corresponding period last year.<br><br>The projected increase in revenue and the turnaround from loss to profit are primarily attributed to: an out-licensing and collaboration agreement with UCB for ATG-201 (CD19×CD3), which took effect from March 2026 and served as the main revenue driver for the period. As previously disclosed in the group's announcement dated July 13, 2026, the group received a $60 million upfront payment from UCB; and an exclusive out-licensing and collaboration agreement with K2 Therapeutics for ATG-106 (CDH6×CD3), effective from June 2026, which generated additional revenue during the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene-B (06996) Issues Profit Alert, Expects First Half Profit of Approximately RMB 195 Million to RMB 238 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene-B (06996) Issues Profit Alert, Expects First Half Profit of Approximately RMB 195 Million to RMB 238 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-28 06:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Antengene-B</b> (<b>06996</b>) has released an announcement. The group anticipates achieving revenue between RMB 490 million and RMB 536 million for the six months ending June 30, 2026, compared to revenue of approximately RMB 53.2 million for the six months ending June 30, 2025.<br><br>For the current period, a profit ranging from RMB 195 million to RMB 238 million is expected, in contrast to a loss of approximately RMB 76.4 million in the corresponding period last year.<br><br>The projected increase in revenue and the turnaround from loss to profit are primarily attributed to: an out-licensing and collaboration agreement with UCB for ATG-201 (CD19×CD3), which took effect from March 2026 and served as the main revenue driver for the period. As previously disclosed in the group's announcement dated July 13, 2026, the group received a $60 million upfront payment from UCB; and an exclusive out-licensing and collaboration agreement with K2 Therapeutics for ATG-106 (CDH6×CD3), effective from June 2026, which generated additional revenue during the period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1118235961","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118235961","pubTimestamp":1785191892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Antengene-B (06996) has released an announcement. The group anticipates achieving revenue between RMB 490 million and RMB 536 million for the six months ending June 30, 2026, compared to revenue of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06996":"德琪医药-B","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"Antengene-B(06996)发布盈利预警，预计上半年盈利约1.95亿元至2.38亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"Antengene-B (06996) has released an announcement. The group anticipates achieving revenue between RMB 490 million and RMB 536 million for the six months ending June 30, 2026, compared to revenue of approximately RMB 53.2 million for the six months ending June 30, 2025.For the current period, a profit ranging from RMB 195 million to RMB 238 million is expected, in contrast to a loss of approximately RMB 76.4 million in the corresponding period last year.The projected increase in revenue and the turnaround from loss to profit are primarily attributed to: an out-licensing and collaboration agreement with UCB for ATG-201 (CD19×CD3), which took effect from March 2026 and served as the main revenue driver for the period. As previously disclosed in the group's announcement dated July 13, 2026, the group received a $60 million upfront payment from UCB; and an exclusive out-licensing and collaboration agreement with K2 Therapeutics for ATG-106 (CDH6×CD3), effective from June 2026, which generated additional revenue during the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}